Overview

  • Product nameAnti-MEK2 antibodySee all MEK2 primary antibodies ...
  • Description
    Rabbit polyclonal to MEK2
  • Tested applicationsELISA, IHC-P, WBmore details
  • Species reactivity
    Reacts with: Mouse, Human
  • Immunogen

    Synthetic peptide from the center region of human MEK2 conjugated to KLH

  • Positive control
    • Mouse liver tissue lysate. Human hepatocarcinoma tissue.

Properties

Applications

Our Abpromise guarantee covers the use of ab71828 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ELISA 1/1000.
IHC-P 1/50 - 1/100.
WB 1/100 - 1/500. Detects a band of approximately 50 kDa (predicted molecular weight: 44 kDa).

Target

  • FunctionCatalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates the ERK1 and ERK2 MAP kinases.
  • Involvement in diseaseDefects in MAP2K2 are a cause of cardiofaciocutaneous syndrome (CFC syndrome) [MIM:115150]; also known as cardio-facio-cutaneous syndrome. CFC syndrome is characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. The inheritance of CFC syndrome is autosomal dominant.
  • Sequence similaritiesBelongs to the protein kinase superfamily. STE Ser/Thr protein kinase family. MAP kinase kinase subfamily.
    Contains 1 protein kinase domain.
  • Post-translational
    modifications
    MAPKK is itself dependent on Ser/Thr phosphorylation for activity catalyzed by MAP kinase kinase kinases (RAF or MEKK1).
    Acetylation of Ser-222 and Ser-226 by Yersinia yopJ prevents phosphorylation and activation, thus blocking the MAPK signaling pathway.
  • Information by UniProt
  • Database links
  • Alternative names
    • Cardiofaciocutaneous syndrome antibody
    • CFC syndrome antibody
    • CFC4 antibody
    • Dual specificity mitogen activated protein kinase kinase 2 antibody
    • Dual specificity mitogen-activated protein kinase kinase 2 antibody
    • ERK activator kinase 2 antibody
    • FLJ26075 antibody
    • MAP kinase kinase 2 antibody
    • MAP2K2 antibody
    • MAPK / ERK kinase 2 antibody
    • MAPK/ERK kinase 2 antibody
    • MAPKK 2 antibody
    • MAPKK2 antibody
    • MEK 2 antibody
    • MEK2 antibody
    • Microtubule associated protein kinase kinase 2 antibody
    • Mitogen activated protein kinase kinase 2 antibody
    • Mitogen activated protein kinase kinase 2 p45 antibody
    • MKK 2 antibody
    • MKK2 antibody
    • MP2K2_HUMAN antibody
    • OTTHUMP00000165826 antibody
    • OTTHUMP00000165827 antibody
    • PRKMK 2 antibody
    • PRKMK2 antibody
    see all

Anti-MEK2 antibody images

  • Anti-MEK2 antibody (ab71828) at 1/100 dilution + mouse liver tissue lysate at 12.5 µg

    Predicted band size : 44 kDa
    Observed band size : 50 kDa (why is the actual band size different from the predicted?)
  • ab71828 at 1/50 dilution, staining MEK2 in human hepatocarcinoma by Immunohistochemistry using formalin-fixed, paraffin-embedded tissue, followed by peroxidase-conjugated secondary antibody and DAB staining.

References for Anti-MEK2 antibody (ab71828)

ab71828 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab71828.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"